KRM Ayurveda Limited Crosses JPY 100+ Crore Revenue Milestone in FY26;H2 FY26 EBITDA Grows ~100% YoY and PAT Surges ~149%, with PAT MarginsNearly Doubling
New Delhi [India], May 5: KRM Ayurveda Limited (NSE: KRMAYURVED), one of India’s emerging integrated Ayurvedic healthcare platforms, announc...
New Delhi [India], May 5: KRM Ayurveda Limited (NSE: KRMAYURVED), one of India’s emerging integrated Ayurvedic healthcare platforms, announced its audited financial results for the year ended March 31, 2026.
Financial Performance Highlights
H2 FY26 vs H2 FY25
| Particulars (₹ In Lakhs) | H2 FY26 | H2 FY25 | YoY Growth |
|---|---|---|---|
| Revenue from operations | 5,333.36 | 4,084.19 | 30.59% |
| EBITDA | 1,787.10 | 884.09 | 102.14% |
| EBITDA Margin (%) | 33.51% | 21.65% | 1,186.00 BPS |
| PAT | 1,189.73 | 478.12 | 148.84% |
| PAT Margin (%) | 22.31% | 11.71% | 1,060.00 BPS |
FY26 vs FY25
| Particulars (₹ In Lakhs) | FY26 | FY25 | YoY Growth |
|---|---|---|---|
| Revenue from operations | 10,169.07 | 7,655.27 | 32.84% |
| EBITDA | 3,112.02 | 1,914.02 | 62.59% |
| EBITDA Margin (%) | 30.60% | 25.00% | 560.02 BPS |
| PAT | 2,012.00 | 1,121.41 | 79.42% |
| PAT Margin (%) | 19.79% | 14.65% | 513.66 BPS |
Key Business Highlights
- Diversified Revenue Mix Driving Stability: KRM’s business model has evolved from being predominantly product-led in FY23, with services contributing just 6.59% of total sales, to a more balanced integrated healthcare model, with services contributing rising to 63.21% in FY26.
- Expanding Integrated Healthcare Footprint: KRM now operates 6 hospitals, 8 clinics, 223+ bed capacity, with 40 physicians and 71 therapists across India.
- IPO-Led Capital Strengthening: Following its ₹ 77 Crore NSE Emerge IPO, KRM strengthened liquidity & positioned itself for telemedicine, expansion, and medical tourism.
Industry Opportunity
- India’s AYUSH market, valued at ~$43 billion in 2024, is projected to reach ~$200 billion by 2030, driven by preventive healthcare, digital health, wellness tourism, and government support.
Growth Drivers
- Telemedicine scale-up
- Tier II/III hospital expansion
- International teleconsultation
- Medical tourism
- Certified Ayurveda training programs
- Expanded product portfolio
- Wider OTC distribution
Speaking on the Company’s Financial and Strategic Performance, Dr. Puneet Dhawan, Managing Director & Promoter, said:
“Our FY26 performance marks a transformational year for KRM Ayurveda as we crossed the %100 crore revenue milestone in FY26, while H2 FY26 EBITDA surged ~102% YoY and PAT grew ~149% YoY, reflecting the strength of our integrated healthcare model and disciplined execution. Our strategic focus on expanding hospitals, specialty care, and digital health is driving stronger margins, improving revenue quality, and deepening consumer trust. Backed by a strengthened post-IPO balance sheet, we are well-positioned to accelerate growth across India and global markets through digital healthcare, medical tourism, and innovation-led Ayurveda solutions.”
